Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederroche.com
Investor Update
Get the latest updates from Investor Update directly as they happen.
Follow now 353 followers
Latest posts
Last updated 1 day ago
Reminder: Invitation to Roche’s Pharma Day 2025
1 day ago
The Roche Investor Relations team would like to invite you to the...
New data for Roche's Vabysmo reinforce its efficacy, safety and durability in neovascular or “wet” age-related macular degeneration (nAMD)
12 days ago
In AVONELLE-X, the largest long-term extension trial in nAMD, disease control and...
Roche and Alnylam advance zilebesiran into global phase III cardiovascular outcomes trial for people with uncontrolled hypertension
18 days ago
Phase III trial informed by comprehensive KARDIA data set generated through three...
Reminder: Invitation to Roche’s Pharma Day 2025
19 days ago
The Roche Investor Relations team would like to invite you to the...
Roche’s Susvimo maintains vision over five years with two refills per year in people with neovascular age-related macular degeneration (nAMD)
about 2 months ago
Susvimo is the only continuous delivery treatment to provide reliable, long-term vision...
Roche presents new insights in Alzheimer’s disease research across its diagnostics and pharmaceutical portfolios at AAIC
about 2 months ago
Trontinemab’s Phase Ib/IIa Brainshuttle™ AD study continues to show rapid and robust...
Roche provides regulatory update on Elevidys™ gene therapy for Duchenne muscular dystrophy in the EU
about 2 months ago
EMA’s CHMP issued an opinion not to recommend Elevidys™ (delandistrogene moxeparvovec) for...
Invitation to Roche’s Pharma Day 2025
about 2 months ago
The Roche Investor Relations team would like to invite you to the...
[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong momentum with 7% growth (CER) in the first half of 2025
about 2 months ago
Group sales grew by 7%1 at constant exchange rates (CER; 4% in...
Roche receives CE Mark for minimally invasive blood test to help rule out Alzheimer’s disease
about 2 months ago
Elecsys pTau181 is the first In Vitro Diagnostic Regulation (IVDR) certified test...
European Commission approves Roche’s Itovebi for people with ER-positive, HER2-negative, advanced breast cancer with a PIK3CA mutation
about 2 months ago
Approval based on INAVO120 data showing the Itovebi™ (inavolisib)-based regimen more than...
Roche’s Board of Directors proposes exchange of Genussscheine for participation certificates (Partizipationsscheine)
about 2 months ago
Participation certificates (Partizipationsscheine) with a nominal value of CHF 0.001 each will...